



## Nephroprotective Influence of Aqueous Decoction of Mulberry Leaves In Hyperglycemia-Induced Oxidative Stress in Brown Rat *Rattus norvegicus* (L).

Vitthalrao Bhimasha Khyade

Science Association, Shardabai Pawar Mahila Mahavidyalaya, Shardanagar Tal. Baramati Dist. Pune – 413115 (India).

---

### Abstract

Streptozotocin induced diabetic male brown rats (*Rattus norvegicus* L.) were divided into five groups, each with 15 individuals. The rats of Group-I served as Normal Healthy group. The Group-II served as streptozotocin induced diabetic rats of solvent treated group. The Group-III served as streptozotocin induced diabetic rats treated with 200 mg/kg decoction of leaves of mulberry, *Morus alba* (L). The Group-IV served as streptozotocin induced diabetic rats treated with 400 mg/kg decoction of leaves of mulberry, *Morus alba* (L). The rats in Group- V were treated with glibenclamide (glyburide) (0.5 mg/kg). All the groups were maintained for three weeks. The blood samples were subjected for bioassays of After 3 weeks, blood samples serum glucose, urea and creatinine. For the purpose to confirm the oxidative damage; attempts on lipid peroxidation and histopathology were conducted. Untreated diabetic rats were found with significant increase in serum glucose, urea and creatinine. Significant rise in lipid peroxidation with a glomerular atrophy and necrotic tubular epithelium in the renal tissue was reported in addition. The rise in serum glucose, urea and creatinine was found ameliorated through the decoction of leaves of mulberry, *Morus alba* (L). The results of the attempt are suggesting that, leaves of mulberry, *Morus alba* (L) are going to serve as effective nutritional supplement to prevent complications of diabetes.

**Keywords:** Oxidative stress, Kidney, mulberry, *Morus alba* (L), Streptozotocin-induced diabetes, Leaf decoction

---

## INTRODUCTION

The pancreas was first identified by Herophilus (335–280 BC), a Greek anatomist and surgeon (*Howard and John Hess Walter, 2012*). A few hundred years later, Rufus of Ephesus, another Greek anatomist, gave the pancreas its name. It was only in 1889 when Oskar Minkowski discovered that removing the pancreas from a dog caused it to become diabetic (insulin was later discovered by Frederick Banting and Charles Herbert Best in 1921). The pancreas is an endocrine and digestive organ that, in humans, lies in the upper left part of the abdomen. It is found behind the stomach. The pancreas is about 15 cm (6 in) long. Anatomically, the pancreas is divided into the head of pancreas, the neck of pancreas, the body of pancreas, and the tail of pancreas. The head is surrounded by the duodenum in its concavity. The head surrounds two blood vessels, the superior mesenteric artery and vein. From the back of the head emerges a small uncinate process which extends to the back of the superior mesenteric vein and ends at the superior mesenteric artery. The neck is about 2.5 cm (1 in) long and lies between the head and the body and in front of the superior mesenteric artery and vein. Its front upper surface supports the pylorus (the base) of the stomach. The neck arises from the left upper part of the front of the head. It is directed first upward and forward, and then upward and to the left to join the body; it is somewhat flattened from above downward and backward. On the right it is grooved by the gastroduodenal artery. The *body* is the largest part of the pancreas and lies behind the pylorus, at the same level as the transpyloric plane. The tail ends by abutting the spleen. The pancreas is a secretory structure with an internal hormonal role (endocrine) and an external digestive role (exocrine). The endocrine part is composed of hormonal tissue distributed along the pancreas in discrete units called islets of Langerhans. Islets of Langerhans have a well-established structure and form density routes through the exocrine tissue. The exocrine part has two main ducts, the main pancreatic duct and the accessory pancreatic duct. These drain enzymes through the ampulla of Vater into the duodenum (*Ionescu-Tirgoviste, et al, 2015*).

Approximately 3 million cell clusters called pancreatic islets are present in the pancreas. Within these islets are four main types of cells which are involved in the regulation of blood glucose levels. Each type of cell secretes a different type of hormone:  $\alpha$  alpha cells secrete glucagon (increase glucose in blood),  $\beta$  beta cells secrete insulin (decrease glucose in blood),  $\delta$  delta cells secrete somatostatin (regulates/stops  $\alpha$  and  $\beta$  cells) and PP cells, or  $\gamma$  (gamma) cells, secrete pancreatic polypeptide. These act to control blood glucose through secreting glucagon to increase the levels of glucose, and insulin to decrease it. The islets are crisscrossed by a dense network of capillaries. The capillaries of the islets are lined by layers of islet cells, and most endocrine cells are in direct contact with blood vessels, either by cytoplasmic processes or by direct apposition. The islets function independently from the digestive role played by the majority of pancreatic cells (*Lakey, et al, 2003*).

Diabetes mellitus type 1 is a chronic autoimmune disorder in which the immune system attacks the insulin-secreting cells of the pancreas. Insulin is needed to keep blood sugar levels within optimal ranges, and its lack can lead to high blood sugar. As an untreated chronic condition, diabetic neuropathy can result. Type 1 diabetes can develop at any age but is most often diagnosed before adulthood. For people living with type 1 diabetes, insulin injections are critical for survival. An experimental procedure to treat type 1 diabetes is the transplantation of pancreatic islet cells from a donor into the patient's liver so that the cells can produce the deficient insulin. Diabetes mellitus type 2 is the most common form of diabetes. The causes for high blood sugar in this form of diabetes usually are a combination of insulin resistance and impaired insulin secretion, with both genetic and environmental factors playing an important role in the development of the disease. The management of type 2 diabetes relies on a series of changes in diet and physical activity with the purpose of reducing blood sugar levels to normal ranges and increasing

insulin sensitivity. Biguanides such as metformin are also used as part of the treatment along with insulin therapy (Longo, *et al*, 2012).

Controlling blood sugar (glucose) levels is vitally important. When these levels rise sharply, as they do after ingesting foods with a high glycemic index such as potatoes or sweets, body responds by producing more insulin to deal with the overload. But if this demand for more insulin occurs too strongly too often, the ability of the pancreas to produce enough insulin may become impaired and our cells may become resistant to insulin as it tries to do its job of facilitating glucose transport through the cell walls. The result is insulin resistance a dangerous condition that, if unchecked, leads to type-2 diabetes. Its primary cause is obesity. Generally speaking, if you are obese, your risk for diabetes is high; if not, it's low (unless you happen to have a genetic predisposition for diabetes) (Andallu, *et al*, 2001).

More than 170 million people are affected by diabetes worldwide, an incidence estimated to rise 50% by 2030, with the greatest increases set to occur in the developing countries of Africa, Asia and South America (WHO, 2008). In Brazil, 7.6 % of the population aged between 30 and 69 years has diabetes, with the cities of São Paulo and Porto Alegre registering the highest percentages: 9.7 and 8.9 %, respectively (Salgado, 1998). Diabetes mellitus is a chronic metabolic disease characterized by hyperglycemia and disturbances in carbohydrate, fat and protein metabolism. It is associated with an absolute or relative deficiency in the secretion of insulin (Diabetes Mellitus 1, DM1) or with insulin resistance (Diabetes Mellitus 2, DM2) (Savage *et al.*, 2007; Stumvoll *et al.*, 2005). DM2 is the most common form of the disease, accounting for 85 to 90% of all recorded cases (Tiwari, Rao, 2002). Besides hyperglycemia, hyperlipidemia is involved in the development of the micro and macro vascular complications of diabetes, which are the major causes of morbidity and death (Tang *et al.*, 2006). Despite the great efforts made to better understand and manage this disease, serious problems such as retinopathy, nephropathy and lower extremity amputation continue to affect patients, while diabetes-related mortality is rising unabated (Tiwari, Rao, 2002). Insulin resistance can also lead to Metabolic Syndrome (MS), a complex metabolic disease characterized by obesity, hypertension, dyslipidemia and DM2 (Sánchez-Salgado *et al.*, 2007). The current rise in DM2 and MS is believed to be a result of an increase in the sedentary life styles combined with ready access to energy-rich food sources in genetically susceptible individuals (Savage *et al.*, 2007).

Treatment of diabetes involves diet control, exercise and the use of hypoglycemic or lipid-lowering drugs such as insulin, sulphonylureas, biguanides and thiazolidinediones (Stumvoll *et al.*, 2005). However, many oral medicines have a number of serious adverse effects, and the management of hyperglycemia and hyperlipidemia with low side effects is still a challenge for the medical system (Revilla-Monsalve *et al.*, 2007). Another problem faced is the cost of the treatment, which is often prohibitively high in developing countries (Schoenfelder *et al.*, 2006). In Brazil, some 200 plants are popularly used for the management of diabetes (Barbosa-Filho *et al.*, 2005). Such plants are used in formulations of home-made medicines such as teas, decoctions and tinctures (Schoenfelder *et al.*, 2006). The main phytochemicals described as useful for treating diabetes are terpenoids, coumarines, flavonoids, alkaloids, phenolic substances and lecithines (Barbosa-Filho *et al.*, 2005).

The leaves of Mulberry, *Morus alba* (L.) leaves have long been used in Chinese medicine for the prevention and treatment of diabetes because as we now know it contains chemical compounds that suppress high blood sugar levels (hyperglycemia) following a carbohydrate-rich meal (Miyahara, *et al*, 2004). A research group in Japan has found that, white mulberry leaves contain compounds that inhibit these intestinal enzymes. Mulberry contains 1-deoxynojirimycin (DNJ) and some of its derivatives like alpha-glucosidase inhibitors that have been used as medicines to treat diabetes mellitus (Mudra, *et al*, 2007; Asai, *et al*, 2011). Alpha-glucosidase enzymes in the intestinal lumen and in the brush border

membrane have a main role in carbohydrate digestion of starch and oligosaccharides to monosaccharides before they are absorbed (Zhong, *et al*, 2006). Suppressing the activity of such digestive enzymes would delay the degradation of starch and oligosaccharides, this would in turn decrease the absorption of glucose and consequently suppress postprandial blood glucose level elevation (Van Der Laar, *et al*, 2005; Dungan, *et al*, 2006; Bonora and Muggeo, 2014). Recently, several studies in animals and humans have reported that mulberry or sericulture products containing DNJ suppress postprandial increases of glucose (Kimura, *et al*, 2007; Nakamura, *et al*, 2009).

It was reported that, certain nitrogen containing sugars were present in mulberry-leaf extract, notably one called 1-deoxynojirimycin, strongly inhibited the intestinal metabolism of disaccharides (especially sucrose), thereby restricting the amount of monosaccharides entered circulation. They also found that, pretreating the rats with mulberry extract before feeding them carbohydrates significantly suppressed normal postprandial (after-meal) rise in blood glucose levels. This beneficial effect occurred in a dose-dependent manner. Doses were however very large: 0.1-0.5g/kg of body weight for a 70-kg (154-lb) human would be 7-35g. (A lower dose 0.02g/kg, corresponding to 1.4g for a human was ineffective). Nonetheless, researchers suggested that mulberry extract might be beneficial in preventing human diabetes by suppressing intestinal alpha-glucosidase activities (Asano, *et al*, 2001). The air dried leaves and fruits of ficus and mulberry were examined in ethanol and hexane extract and evaluated against hyperlipidemia by estimating the rate limiting enzyme of cholesterol biosynthesis. *Ficus mysorensis* (hexane extract) was evaluated in vivo by lipid profile estimation in hypercholesterolemic rats. Hexane fraction was chromatographed and six isolated compounds were identified. *Ficus mysorensis* recorded hypolipidemic activity (Lee, *et al*, 2007; Awad, *et al*, 2012). Effect of *Morus nigra* (Aqueous extract) on artificially induced diabetic and non-diabetic rats and recorded the lipid profile. In diabetic rats, plant treatment caused reduced MDA, cholesterol, triglycerides and VLDL levels. *Morus nigra* treatment reduced the incidence of internal anomalies in offspring from diabetic rats (Volpato, *et al*, 2011).

Mulberry therapies were conducted on type-2 streptozotocin induced diabetic rats showed improvement in fasting blood glucose levels. Quercetin, the quantitatively major flavonoids glycoside in mulberry leaves effectively suppressed the blood glucose levels (Katsube, *et al*, 2010). Daily consumption of mulberry leaves improved hyperglycemia in diabetic rats and reduced oxidative stress in liver (Kim, *et al*, 2011). Beverages containing mulberry leaf (*Morus alba*) are believed to promote good health, especially people with diabetes in Thailand and the effect of long term administration of an ethanolic extracts of mulberry leaf was studied in blood glucose. Daily administration of 1g/kg of MA for six weeks decreased blood glucose by 22% which was comparable to the effect of 4v/kg insulin. Findings indicated that long term supplement of *Morus alba* has anti-hyperglycemic effects in chronic diabetic rats (Naowaboot, *et al*, 2009; Sun, *et al*, 2011).

*Morus nigra* leaves were collected from different locations of Jordan and used for the treatment of diabetic symptoms. It was determined by DPPH and ABTS assays in relation to the total phenolic contents of fruit, roots and shoots of mulberry. *Morus nigra* extract and its potential use in radical scavenging made Jordanian population to extensively use the plants as a traditional anti-diabetic agent (Ahme, *et al*, 2008). Antioxidant role of mulberry (*Morus indica*) on the various antioxidant enzymes in rat erythrocytes like glutathione per-oxidase, glutathione reductase, glutathione-S-transferase and super oxide dismutase observed in uncontrolled diabetes were improved by treating with mulberry very efficiently (Andallu, *et al*, 2003; Fang, *et al*, 2005).

The mulberry is often tried in order to help treat diabetes. It is also tried for treating high cholesterol levels, high blood pressure, the common cold and its symptoms, muscle and joint pain such as from arthritis, constipation, dizziness, ringing in the ears, hair loss, and premature graying. The leaves; bark

and the fruits of Mulberry, *Morus alba* (L.) deserve appreciable medicinal potential. Therefore, tree of mulberry exert a therapeutic influence. In one of the recent attempt in laboratory of author, treating the diabetic experimental animals with mulberry leaf decoction for continuous 14 days was found resulted into lowering the glucose levels in the blood. It was also resulted into restraint glycogen loss in liver, and alteration in histological structure of pancreatic tissues and renal tissues. The Administration of mulberry leaf decoction at the rate twenty grams per liter was found to be able to regulate the altered metabolic processes. Mulberry, *Morus alba* (L.) should be explored as medicinal plant to be used to control the diabetes. Mulberry leaves could be a promising therapeutic option for modulating diabetic risks (Vitthalrao Bhimasha Khyade, 2018). However, further investigations should be performed to substantiate the potential of mulberry leaves in practical uses. Diabetogenic hyperglycemia leads to increased production of reactive oxygen species (ROS). These reactive oxygen species in the form of free radicals are implicated in the complications of diabetes. Various animal studies have proved that hyperglycemia-induced oxidative stress causes a reduction in beta cell mass and impairment in its function (Tokuyama, *et al*, 1995 and Ihara, *et al*, 1999). Ethanolic leaf extract of mulberry, *Morus alba* (L) on 7,12-dimethylbenz(a)anthracene (DMBA)- induced buccal pouch carcinoma in Syrian hamster, *Mesocricetus auratus* (L). Oral squamous cell carcinoma was developed in the buccal pouch of Syrian golden hamsters, by painting with 0.5%

DMBA in liquid paraffin, thrice a week, for 14 weeks. The tumor incidence, volume and burden were determined. Oral administration of ethanol extractives of leaves of mulberry, *Morus alba* (L) at a dose of 300 mg/kg, body weight, to DMBA (on alternate days for 14 weeks)- painted animals significantly prevented the incidence, volume and burden of the tumor. The ethanol extractives of leaves of mulberry, *Morus alba* (L) showed potent antilipidperoxidative effect, as well as enhanced the antioxidant status in DMBA painted animals (Vitthalrao B. Khyade and Sadhana D. Deshpande, 2015).

Epidemiological studies, clinical trials and animal experimental models have proved that dietary supplementation of antioxidants like vitamin E, vitamin C, etc., has reduced the incidence of oxidative damage related disorders such as ageing, cardiovascular diseases, diabetes, inflammation, and neurodegenerative disorder (Stahl, 1997). Ahmadvand (2012) reported that the coenzyme Q10 a natural antioxidant showed significant nephroprotective effect in diabetic rats compared with untreated diabetic animals. Flavonoids (more than 8000) constitute the largest and most important groups of polyphenolic compounds in fruits, vegetables, wine, tea and cocoa (Ross and Kasum, 2002). Recent attention has been focused on the potential use of flavonoids-based drugs for the prevention and treatment of oxidative stress-mediated diseases. Flavonoids can exert their antioxidant activity by various mechanisms, e.g., by scavenging or quenching free radicals, by chelating metal ions, or by inhibiting enzymatic systems responsible for free radical generation. Hence, the present study was done to explore the nephroprotective effect of mulberry decoction against hyperglycemia-induced oxidative stress in streptozotocin induced diabetic brown Rat, *Rattus norvegicus* (L.).

## **MATERIAL AND METHOD**

The study was carried through the steps, which include: Preparation of leaf decoction; Rearing of experimental animals; Induction of Diabetes; Grouping the experimental animals; Mulberry Decoction Treatment; Serum preparation; Tissue sampling; Light microscopic study; Biochemical analysis and Statistical analysis.

(A). Preparation of Leaf Decoction: The eaves of mulberry, *Morus alba* (L.) were collected from mulberry garden of Sericulture Unit, Malegaon Sheti Farm, Agricultural Development Trust Baramati, Shardanagar, (Malegaon Khurd) Post Box No - 35, Baramati, Pune 413 115, Maharashtra, India and were identified, confirmed in the "Dr. APIS" Laboratory (Shrikrupa Residence, Teachers Society, Malegaon

Colony, Baramati Dist. Pune – 413115 Maharashtra, India) The leaves of mulberry, *Morus alba* (L.) were kept in a dry and ventilated place, protected from light. The leaves were shade dried and powdered. The decoct (20 g/L) was prepared daily, boiled for 10 minutes and when reaching room temperature, the solution was filtered and used for administration to the rats as a drinkable solution.

(B). Rearing of Experimental Animals: Male rat of the species *Rattus norvegicus* (L.), weighing  $164.97 \pm 11.69$  g (mean  $\pm$  SEM, n= 70), bred in “Dr. APIS” Laboratory, were used in the present attempt. The rats were housed in an environmentally-controlled room with a 12 h light: 12 h dark cycle (lights on at 7:00 am) at a constant temperature of 23 °C. All the experimental procedures were carried out in accordance with the guidelines of the National Centre for Laboratory Animal Sciences (NCLAS) of National Institute of Nutrition (NIN) Hyderabad India. The experimental protocol was approved by the Research Ethics Committee of the National Centre for Laboratory Animal Sciences (NCLAS).

(C). Induction of Diabetes:

After two weeks of acclimatization, the diabetes was induced in rats with Streptozotocin (STZ, Sigma Chemical Company). Streptozotocin (STZ) was intraperitoneally administered in a dose of 70 mg/kg/bw in 0.1 M citrate buffer, (pH 4.5). The control rats received intraperitoneally citrate buffer. A freshly-prepared solution of streptozotocin (STZ, 70 mg/kg/bw) in 0.1 M citrate buffer, pH 4.5 was injected intraperitoneally to rats that had fasted overnight (Kesari *et al.*, 2007). One week later, blood samples were collected from the orbital sinus, and rats with fasting blood glucose (FBG) levels above 200 mg/dL (11.1 mmol/L) were selected for the experimental protocol. During a 21-day period of treatment, normal and STZ-treated rats were fed with 40 g/day of pellet food (**Hindustan Animal Feeds**, Behind Gokulnagar Octroi Check Post, Near Vijaynagar Railway Crossing, Jamnagar – 361004 Gujarat INDIA).

(D). Grouping the Animals (Design of the Attempt):

The design of the experimentation as per the guidelines explained by Lal, *et al* (2012). After diabetic state was confirmed, the rats were placed in one untreated control group and four into the four experimental groups (n=15 animals/ group). Thus total five groups of animals were made.

The rats of Group-I served as Normal Healthy group.

The Group-II served as streptozotocin induced diabetic rats of solvent treated group.

The Group-III served as streptozotocin induced diabetic rats treated with 200 mg/kg decoction of leaves of mulberry, *Morus alba* (L).

The Group-IV served as streptozotocin induced diabetic rats treated with 400 mg/kg decoction of leaves of mulberry, *Morus alba* (L).

The rats in Group- V were treated with glibenclamide (glyburide) (0.5 mg/kg).

(E). Mulberry Decoction Treatment:

The mulberry decoction treatment was carried out everyday morning using intragastric tube for 3 weeks after induction of diabetes. The intragastric tube is a feeding tube. It is a medical device used to provide nutrition to experimental animals (and also to the patients that cannot obtain nutrition through mouth) The state of being fed by a feeding tube is called gavage, enteral feeding or tube feeding. The feeding tube used in the attempt were usually made of polyurethane.

**(F). Serum preparation**

The whole blood was collected from rats of each group in sterile, covered test tubes and labeled. After collection of the whole blood, it was allowed to clot undisturbed for 15-30 mins. The clot was removed

by centrifuging at 1000-2000  $\times g$  for 10 mins in a centrifuge. The supernatant serum was obtained for biochemical analysis.

### **(G). Tissue sampling**

The animals were sacrificed by cervical dislocation and the kidneys from all the groups of rats were dissected out. They were processed for histopathological examination (HPE) and biochemical analysis.

### **(H). Light microscopic study**

For histopathological study the rat tissues were perfused with 10% formalin. The kidneys of the rats were excised immediately from the abdominal cavity and fixed in 10% neutral formalin, dehydrated in graded alcohol (80-100%), cleaned in xylene and embedded in paraffin. Then renal tissues were sliced into 3-5  $\mu m$  pieces with a rotary microtome, deparaffinized in xylene, passed through varying grades of alcohol and finally stained with hematoxylin and eosin for histopathological assessment. The specimens were evaluated with a light microscope. All histopathological changes were examined by pathologist.

### **(I). Biochemical analysis**

Blood urea was estimated by urease method and serum creatinine was estimated by modified Jaffe's method (Allain, *et al*, 1974). Concentration of thiobarbituric acid reactive substances in the tissues was estimated by the method of Niehaus and Samuelsson (Niehaus and Samuelsson, 1968). Reduced glutathione in the tissues were estimated by the method of Ellman (Ellman, 1959). Superoxide dismutase (SOD) in the tissues was assayed by the method of Kakkar *et al*, and the activity of catalase (CAT) in the tissues were determined by the method of Sinha (Kakkar, *et al*, 1984; Sinha, 1972).

#### **(J). Statistical Analysis:**

The results were expressed as mean  $\pm$  S.E.M. (standard error). Comparisons were made using one-way ANOVA followed by Duncan's and Bonferroni's *post-hoc* tests. In all comparisons, values of  $p < 0.05$  were considered statistically significant. Statistical tests were performed using the SPSS program (Statistical Package for Social Sciences, version 10.0, for Windows <https://spss.en.softonic.com/> ).

## **RESULTS AND DISCUSSION**

The results on Influence of Leaf Decoction of Mulberry, *Morus alba* (L.) on Streptozotocin Induced Diabetes in Brown Rat, *Rattus norvegicus* (L.) are explained parameter-wise. The parameters include: Physiological Parameters; Glucose level; Lipid Peroxides and Antioxidants; Serum urea and creatinine and Histopathology

### **Effect of Leaf Decoction of Mulberry, *Morus alba* (L.) on blood glucose levels in Streptozotocin Induced Diabetes in Brown Rat, *Rattus norvegicus* (L.):**

The glucose readings were compared to readings obtained for diabetic control rats and mulberry decoction treated rats. In streptozotocin induced diabetic rats, the blood glucose levels remained significantly high for all the three weeks of study. The mulberry decoction treated rats showed a significant reduction in blood glucose levels from the second week after induction. The mulberry decoction treated rats showed maximum reduction in blood glucose level on twenty first day at 400 mg/kg. In glibenclamide treated rats, blood glucose levels were significantly lower for all the three weeks of the study (Table 1).

### **Effect of Leaf Decoction of Mulberry, *Morus alba* (L.) on Lipid Peroxides and Antioxidants in Kidneys in Streptozotocin Induced Diabetes in Brown Rat, *Rattus norvegicus* (L.):**

Significantly higher level of Lipid Peroxides was reported in the diabetic rats in comparison with normal healthy individuals. The diabetic rats treated with mulberry decoction showed significant reduction in the level of Lipid Peroxides. The antioxidant levels were significantly ( $p < 0.05$ ) higher in diabetic rats treated with mulberry decoction in a dose-dependent manner in comparison with untreated diabetic rats. The Lipid Peroxides level in glibenclamide treated rats was significantly lower than the diabetic and mulberry decoction treated rats in the study. The glibenclamide treated rats also showed significant increase in antioxidant levels compared with diabetic rats (Table 2).

### **Effect of Leaf Decoction of Mulberry, *Morus alba* (L.) on Serum Urea and Creatinine in Streptozotocin Induced Diabetes in Brown Rat, *Rattus norvegicus* (L.):**

The serum urea and creatinine levels were increased significantly in streptozotocin induced diabetic rats, compared to normal healthy control rats at the end of third week in the study. The rats treated with mulberry decoction after induction of diabetes showed significant ( $p < 0.05$ ) reduction in serum urea and creatinine in a dose-dependent manner compared to untreated diabetic rats. Glibenclamide treated rats also showed significant ( $p < 0.05$ ) reduction in serum urea and creatinine compared with diabetic rats (Table 3).

#### **Histopathological Observation:**

Compared to the photomicrograph of renal cortex of normal healthy rats (Figure 1), the diabetic rats showed renal cellular injury, necrotic tubular epithelium with widening of Bowman's capsule and the glomerular atrophy (Figure 2). Diabetic rats treated with mulberry decoction at 200 mg/kg showed severe glomerular atrophy and necrosis of tubular epithelial cells (Figure 3). However at mulberry decoction 400 mg/kg, the renal cortex showed only mild swelling and congestion in the renal epithelium. There was no necrosis and the glomerular atrophy (Figure 4). In diabetic rats treated with glibenclamide, the renal cortex showed moderate degeneration of renal epithelium, atrophied renal corpuscle and mild glomerular capillaries congestion (Figure 5).

The findings of the Diabetic Complications and Control Trial (DCCT) and The United Kingdom Prospective Diabetic Study support the concept that chronic hyperglycemia plays a causative role in the pathogenesis of diabetic micro and macrovascular complications (Triplitt, *et al.*, 2011). Diabetic nephropathy is the leading contributor to end-stage renal disease. Hyperglycemia leads to increased production of ROS or superoxide in the mitochondria from glucose auto-oxidation, protein glycosylation and glucose metabolism via sorbitol pathway. The ROS and glycosylation lead to disruption of cellular function, oxidative damage to the membrane and other structures, susceptibility to LPO and exhaustion of antioxidant defences. Al-Enazi had reported rise in LPO in hepatic cells due to hyperglycemia induced by streptozotocin in rats. (Al-Enazi, 2014). In the present study also the diabetic rats showed an increase in LPO and decreased in antioxidants in the renal tissue. The oxidative damage to renal cell was further confirmed by increase in serum urea and creatinine in diabetic rats.

There are reports that natural antioxidants such as vitamin E, caffeic acid, lipoic acid, quercetin, melatonin and natural phenolic compounds have protective effects against hyperglycemia-induced oxidative stress (Balkis, *et al.*, 2009; Garfinkel, *et al.*, 2011). Treatment of diabetic animals with silymarin significantly reduced LPO and increased the levels of SOD, glutathione reductase and CAT. SOD protects tissues against oxygen free radicals by scavenging oxygen. Thus, SOD can act as a primary defense against oxygen and prevents further generation of free radicals (Arivazhagan *et al.*, 2000). CAT



protects tissues from highly reactive OH radicals (Sozmen *et al.*, 2001). Mulberry decoction by scavenging the free radicals and by raising the antioxidant activities prevented the renal damage and maintained the cell integrity. The Diabetic Complications and Control Trial (DCCT) demonstrated that the improvement of glycemic control reduced microalbuminuria (39%) and clinical nephropathy (54%) (Powers, 2005). Varzi *et al.* (2007) had reported that silymarin improved alteration in serum creatinine concentration in gentamicin treated dogs (Varzi *et al.*, 2007). In the present attempt also mulberry decoction treated diabetic animals showed a decrease in serum urea and creatinine, which confirms its nephroprotective effect. Next step on this line to plan to study the cytoprotective action of mulberry decoction against hyperglycemia-induced oxidative stress. The histopathological study of renal tissue of diabetic rats showed the glomerular atrophy with necrosis of tubular epithelium. This damage was due to hyperglycemia. In mulberry decoction treated diabetic rats there was restoration of glomerular structure, with only mild congestion in tubular epithelium.

## CONCLUSION

This attempt proved that the leaf decoction of mulberry, *Morus alba* (L.) had significant nephroprotective effect against the hyperglycemia-induced oxidative stress in Streptozotocin induced diabetes Brown Rat, *Rattus norvegicus* (L.). The excellent safety; ease in it's availability and low cost of leaf decoction of mulberry, *Morus alba* (L.) are the advantages. Hence, leaf decoction of mulberry, *Morus alba* (L.) may be added as an adjuvant therapy for preventing or slowing the progression of diabetic nephropathy.

Table 1: Influence of mulberry leaf decoction on blood glucose levels in streptozotocin induced diabetic Brown Rat, *Rattus norvegicus* (L.).

Day after Treatment Group	Day 1 (mg/dl)	Day 17 (mg/dl)	Day 14 (mg/dl)	Day 21 (mg/dl)
Normal Healthy	78.01±4.45 <sup>d</sup>	78.01±4.45 <sup>e</sup>	78.01±4.45 <sup>e</sup>	78.01±4.45 <sup>e</sup>
Diabetic Solvent treated	206.33±2.58 <sup>b</sup>	188.83±4.83 <sup>a</sup>	205.17±9.52 <sup>a</sup>	206.00±10.95 <sup>a</sup>
Diabetic Treated With Mulberry Decoction (200 mg/kg)	202.83±8.73 <sup>b</sup>	175.68± 5.15 <sup>b</sup>	158.50±9.39 <sup>b</sup>	126.34±1.64 <sup>b</sup>
Diabetic Treated With Mulberry Decoction (400 mg/kg)	209.43±11.4 <sup>a</sup>	172.18±2.98 <sup>c</sup>	144.84±6.22 <sup>c</sup>	119.68±3.11 <sup>c</sup>
Diabetes Treated With	198.68±5.14 <sup>c</sup>	154.34±3.45 <sup>d</sup>	132.18±6.16 <sup>d</sup>	107.86±2.16 <sup>d</sup>

Glibenclamide (0.5 mg/kg)				
---------------------------	--	--	--	--

Values are expressed as means±SD for six rates in each group. Values not sharing a common superscript differ significantly at p≤0.05 (Duncken's test). SD: Standard deviation

Table 2: Influence of mulberry leaf decoction on Lipid Peroxidation and Antioxidants in kidneys in streptozotocin induced diabetic Brown Rat, *Rattus norvegicus* (L.).

Parameter Group	SOD (unit/mg protein)	GSH (µg/mg protein)	CAT (µmol/mg protein)	Lipid Peroxidation (mmole/100 g tissue)
Normal Healthy	16.01±0.36 <sup>a</sup>	32.73±0.87 <sup>b</sup>	20.52±0.98 <sup>a</sup>	3.56±0.37 <sup>d</sup>
Diabetic Solvent treated	5.12±0.59 <sup>c</sup>	8.11±0.22 <sup>e</sup>	3.39±0.47 <sup>e</sup>	16.58±0.38 <sup>a</sup>
Diabetic Treated With Mulberry Decoction (200 mg/kg)	11.13±0.72 <sup>d</sup>	20.38±0.44 <sup>d</sup>	17.93±0.73 <sup>c</sup>	8.74±0.91 <sup>b</sup>
Diabetic Treated With Mulberry Decoction (400 mg/kg)	15.32±0.47 <sup>b</sup>	30.58±0.79 <sup>c</sup>	17.74±0.68 <sup>a</sup>	8.18±0.46 <sup>c</sup>
Diabetes Treated With Glibenclamide (0.5 mg/kg)	13.87±0.13 <sup>c</sup>	32.08±1.19 <sup>a</sup>	18.26±0.65 <sup>b</sup>	3.43±0.73 <sup>e</sup>

Values are expressed as mean±SD for six rates in each group. Values not sharing a common superscript differ significantly at p≤0.05 (Duncken's test). SD: Standard deviation, LPO: Lipid peroxides, SOD: Superoxide dismutase, GSH: Glutathione, CAT: Catalase

Table 3: Influence of mulberry leaf decoction on Serum Urea and Serum Creatinine in streptozotocin induced diabetic Brown Rat, *Rattus norvegicus* (L.).

Parameter Group	Urea(mg/dl)	Creatnine (mg/dl)
Normal Healthy	27.13±1.78 <sup>e</sup>	0.59±0.06 <sup>e</sup>
Diabetic Solvent treated	75.16±4.31 <sup>a</sup>	1.78±0.11 <sup>a</sup>
Diabetic Treated With Mulberry Decoction (200 mg/kg)	49.46±0.98 <sup>b</sup>	1.66±0.13 <sup>b</sup>
Diabetic Treated With Mulberry Decoction (400 mg/kg)	31.31±0.57 <sup>d</sup>	0.64±0.05 <sup>d</sup>
Diabetes Treated With Glibenclamide (0.5 mg/kg)	31.42±0.78 <sup>c</sup>	0.73±0.03 <sup>c</sup>

Values are expressed as mean±SD for six rates in each group. Values not sharing a common superscript differ significantly at  $p \leq 0.05$  (Duncken's test). SD: Standard deviation

## REFERENCES

1. Ahmad A, Gupta G, Afzal M, Kazmi I, Anwar F. Antiulcer and antioxidant activities of a new steroid from *Morus alba*. *Life Sci*, 2013; 92(3): 202-210.
2. Ahmadvand H. (2012). Effects of coenzyme Q10 on hemoglobin A1C, serum urea and creatinine in alloxan-induced type 1 diabetic rats. *Iran J Pharmacol Ther*. 2012;11:64-7.
3. Ahmed H. Al-Mustafa, Osama Y. Al-Thunibat. Antioxidant activity of some Jordanian Medicinal plants used traditionally for treatment of Diabetes. *Pak J Biol Sci*, 2008; 11(3): 351-358.
4. Ahmed S, Shakeel F. Voltammetric determination of antioxidant character in *Berberis lycium* Royel. *Zanthoxylum armatum* and *Morus nigra* Linn. plants. *Pak J Pharm Sci*, 2012; 25(3): 501-507.
5. Ahmed, I.; Adeghate, E.; Sharma, A. K.; Pallort, D. J. Singh, J. (1998). Effects of *Momordica charantia* fruit juice on islet morphology in the pancreas of streptozotocin-diabetic rat. *Diabetes Res. Clin. Pract.*, v.40, p.145-151.
6. Ajitha M, Rajnarayana K. *Indian Drugs*. 2001; 38(11): 545-553.
7. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. (1974). Enzymatic determination of total serum cholesterol. *Clin Chem*. 1974;20(4):470-5.
8. Amalesh S, Gouranga D, Sanjoy KD. Roles of flavonoids in plants. *Int J Pharm Sci Tech*, 2011; 6(1): 12-35.
9. and lipid profile of streptozotocin-induced diabetic rats. *J Ethno pharmacol*, 2011; 138: 691-696.
10. Andallu B, Suryakantham V, Srikanthi BL, Reddy GK. Effect of mulberry (*Morus indica* L.) therapy on plasma and erythrocyte membrane lipids in patients with type 2 diabetes. *Clin Chim Acta*, 2001; 314: 47-53.

11. Andallu B, Varadacharyulu Nch. Antioxidant role of mulberry (*Morus indica* L. cv. Anantha) leaves in streptozotocin-diabetic rats. *Clin Chim Acta*, 2003; 338(1-2): 3-10.
12. Asai A, Nakagawa K, Higuchi O, Kimura T, Kojima Y, Kariya J, Miyazawa T, Oikawa S. Effect of mulberry leaf extract with enriched 1-deoxynojirimycin content on postprandial glycemic control in subjects with impaired glucose metabolism. *J Diabetes Investigation*, 2011; 2(4): 318-323.
13. Asano N, Yamashita T, Yasuda K, Ikeda K, Kizu H, Kameda Y, Kato A, Nash RJ, Lee HS, Ryu KS. Polyhydroxylated alkaloids isolated from mulberry trees (*Morus alba* L.) and silkworms (*Bombyx mori* L.). *J Agric Food Chem*, 2001; 49: 4208-4213.
14. Awad NE, Seida AA, Hamed MA, Hosny AM, Elbatanony MM. Phytochemical and in vitro screening of some *Ficus* and *Morus* spp. For hypolipidaemic and antioxidant activities and in vivo assessment of *Ficus mysorensis* (Roth.). *Nat Prod Res*, 2012; 26: 1101-1111.
15. Bae SH, Suh HJ. Antioxidant activities of five different mulberry cultivars in Korea. *LWT-Food Sci Technol*, 2007; 40: 955-962.
16. Ballve, A. C.; Siqueira, N. C. S.; Mentz, L. A.; Silva, G. A. B.; Jose, K. F. D. (1995). Plantas medicinais de uso popular. Atlas Farmacognóstico. Canoas: Editora da ULBRA, p.205.
17. Barbosa\_Filho, J. M.; Vasconcelos, T. H. C.; Alencar, A. A.; Batista, L. M.; Oliveira, R. A. G.; Guedes, D. N.; Falcao, H. S.; Moura, M. D.; Diniz, M. F. F. M.; Modesto-Filho, J. (2005). Plants and their active constituents from South, Central, and North America with hypoglycemic activity. *Rev. Bras. Farmacogn.*, v.15, p.392-413.
18. Berglund L, Brunzell JD, Goldberg AC, et al. (September 2012). "Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline". *J. Clin. Endocrinol. Metab.* **97** (9): 2969–89. doi:10.1210/jc.2011-3213. PMC 3431581 . PMID 22962670.
19. Biavatti, M. W.; Farias, S. N.; Prado, S. R. T. (2004). Preliminary studies on *Campomanesia xanthocarpa* (Berg.) and *Cuphea carthagenensis* (Jacq.) J. F. Macbr. aqueous extract: weight control and biochemical parameters. *J. Ethnopharmacol.*, v.393, p.385-389.
20. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. *Diabetologia*, 2001; 44: 2107-2114.
21. Broadhurst, C. L.; Polansky, M. M.; Anderson, R. A. (2000). Insulin like biological activity of culinary and medicinal plant aqueous extraction *in vitro*. *J. Agri. Food Chem.*, v.48, p.849-52.
22. Butt MS, Nazir A, Sultan MT, Schroen K. *Morus alba* L. nature's functional tonic. *Trends Food Sci Technol*, 2008; 19: 505-512.
23. Cavalli, V. L. L. O.; Sordil, C.; Toninil, K.; Grandol, A.; Muneronl, T.; Guigil, A.; Roman-Junior, W. A.(2007). Avaliação in vivo do efeito hipoglicemiante de extratos obtidos da raiz e folha de bardana *Arctium minus* (Hill.) Bernh. *Rev. Bras. Farmacogn.*, v.17, p.64-70.
24. Chan KC, Ho HH, Huang CN, Lin MC, Chen HM, Wang CJ. Mulberry leaf extract inhibits vascular smooth muscle cell migration involving a block of small GTPase and Akt/NF-kappaB signals. *J Agric Food Chem*, 2009; 57: 9147-9153.
25. Chao WW, Kuo YH, Li WC, Lin BF. The production of nitric oxide and prostaglandin E2 in peritoneal macrophages is inhibited by *Andrographis paniculata*, *Angelica sinensis* and *Morus alba* ethyl acetate fractions. *J Ethnopharmacol*, 2009; 122(1): 68-75.
26. Chen J, Li X. Hypolipidemic effect of flavonoids from mulberry leaves in triton WR-1339 induced hyperlipidemic mice. *Asia Pac J Clin Nutr*, 2007; 16: 290-294.
27. Chen Z, Zhu C, Han Z. Effects of aqueous chlorine dioxide treatment on nutritional components and shelf-life of mulberry fruit (*Morus alba* L.). *J Biosci Bioeng*, 2011; 111(6): 675-681.
28. Choi EM, Hwang JK. Effects of *Morus alba* leaf extract on the production of nitric oxide, prostaglandin E2 and cytokines in RAW2647 macrophages. *Fitoterapia*, 2005; 76: 608-613.

29. Colonna M, Danzon A, Delafosse P, Mitton N, Bara S, Bouvier AM. Cancer prevalence in France: time trend situation in 2002 and extrapolation to 2012. *Eur J Cancer*, 2008; 44: 115-122.
30. Cui X, Wang H, Liu C, Chen RY. Study of antioxidant phenolic compounds from stem barks of *Morus yunnanensis*. *Zhongguo Zhong Yao Za Zhi*, 2008b; 33(13): 1569-1572.
31. Cui XQ, Wang L, Yan RY, Tan YX, Chen RY, Yu DQ. A new Diels-Alder type adducts and two new flavones from the stem bark of *Morus yunnanensis* Koidz. *J Asian Nat Prod Res*, 2008a; 10(3-4): 361-366.
32. Daimon T, Hirayama C, Kanai M, Ruike Y, Meng Y, Kosegawa E, Nakamura M, Tsujimoto G, Katsuma S, Shimada T. The silkworm Green b locus encodes a quercetin f-O-glucosyltransferase that produces green cocoons with UV-shielding properties. *Proc Natl Acad Sci USA*, 2010; 107(25): 11471-11476.
33. Darias-Martin J, Lobo-Rodrigo G, Hernandez-Cordero J, Diaz-Diaz E, Diaz-Romero C. Alcoholic beverages obtained from black mulberry. *Food Technol Biotech*, 2003; 41(2): 173-176.
34. Das BC, Krishnaswami S. Some observations on interspecific hybridization in mulberry. *Indian J Seric*, 1965; 4: 1-8.
35. Datta RK. Mulberry Cultivation and Utilization in India. FAO. Electronic conference on mulberry for animal production, Mulberry cultivation and utilization in India. Rome, Italy, 2000; 45-62.
36. Deshmukh SV, Pathak NV, Takalikar DA. Nutritional effect of mulberry (*Morus alba*) leaves as sole ration of adult rabbits. *World Rabbit Sci J*, 1993; 1: 67-69.
37. Diani, A. R.; SAWADA, G.; WYSE, B.; MURRAY, F. T.; Khan, M. (2004). Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. *Am. J. Physiol. Endocrinol. Metab.*, v.286, p.E116-E122.
38. Dickel, M. L.; Rates, S. M. K.; Ritter, M. R. (2007). Plants popularly used for losing weight purposes in Porto Alegre, South Brazil. *J. Ethnopharmacol.*, v.109, p.60-71.
39. Dobrzynski, E.; Montanari, D.; Agata, J.; Zhu, J.; Chao, J.; Chao, L. (2002). Adrenomedullin improves cardiac function and prevents renal damage in streptozotocin-induced diabetic rats. *Am. J. Physiol. Endocrinol. Metab.*, v.283, p.1291-1298.
40. Doi K, Kojima T, Makino M, Kimura Y, Fujimoto Y. Studies on the constituents of the leaves of *Morus alba* L. *Chem Pharm Bull*, 2001; 49(2): 151-153.
41. Dungan KM, Buse JB, Largay J. 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. *Diabetes Care*, 2006; 29: 1214-1219.
42. Durrington, P (August 2003). "Dyslipidaemia". *The Lancet*. **362** (9385): 717-31. doi:10.1016/S0140-6736(03)14234-1. PMID 12957096.
43. El-Beshbishy HA, Singab ANB, Sinkkonen J, Pihlaja K. Hypolipidemic and antioxidant effects of *Morus alba* L. (Egyptian mulberry) root bark fractions supplementation in cholesterol-fed rats. *Life Sci*, 2006; 78: 2724-2733.
44. Elfalleh W, Tili N, Nasri N, Yahia Y, Hannachi H, Chaira N. Antioxidant capacities of phenolic compounds and tocopherols from *tunisian pomegranate (Punica granatum)* fruits. *J Food Sci*, 2011; 76: 707-713.
45. Ellman GL. (1959). Tissue sulfhydryl groups. *Arch Biochem Biophys*. 1959;82(1):70-7.
46. Elmaci Y, Altug T. Flavour evaluation of three black mulberry (*Morus nigra*) cultivars using GC/MS. Chemical and sensory data. *J Sci Food Agric*, 2002; 82(6): 632-635.
47. Enkhmaa B, Shiwaku K, Katsube T, Kitajima K, Anuurad E, Yamasaki M, Yamane Y. Mulberry (*Morus alba* L.) leaves and their major flavonol quercetin 3-(6-malonylglucoside) attenuate atherosclerotic lesion development in LDL receptor-deficient mice. *J Nutr*, 2005; 135: 729-734.

48. Ercisli S, Orhan E. Chemical composition of white (*Morus alba*), red (*Morus rubra*) and black (*Morus nigra*) mulberry fruits. *Food Chem*, 2007; 103: 1380-1384.
49. Fang SH, Hou YC, Chao PD. Pharmacokinetic and pharmacodynamic interactions of morin and. *J Nutr*, 2005; 135(4): 729-734.
50. Fernandes, J. B. F.; Vargas, V. M. S. (2003). Mutagenic and antimutagenic potential of the medicinal plant *M. laevigata* and *C. xanthocarpa*. *Phytochem. Res.*, v.17, p.269-273.
51. Ferreira, L. D. M. C. B.; Brau, L.; Nikolovski, S.; Raja, G.; Palmer, T. N.; Fournier, A. P. (2001). Effect of streptozotocin-induced diabetes on glycogen resynthesis in fasted rats post-high-intensity exercise. *Am. J. Physiol. Endocrinol. Metab.*, v.280, p.83-91.
52. Geary, N.; Langhans, W.; Scharrer, E. (1981). Metabolic concomitants of glucagons-induced suppression of feeding in the rat. *Am. J. Physiol. Regul. Integr. Comp. Physiol.*, v.241, p.R330-R335.
53. Gerasopoulos D, Stavroulakis G. Quality characteristics of four mulberry (*Morus* spp.) cultivars in the area of Chania Greece. *J Sci. Food Agric*, 1997; 73: 261-264.
54. Goud PB, Kachole MS. Antioxidant enzyme changes in neem, pigeonpea and mulberry leaves in two stages of maturity. *Plant Signal Behav*, 2012; 7(10): 1258-1262.
55. Grover, J. K.; Yadav, S.; Vats, V. (2002). Medicinal plants of India with anti-diabetic potential. *J. Ethnopharmacol.*, v.81, p.81-100.
56. Ha US, Koh JS, Kim HS, Woo JC, Kim SJ, Jang H, Yoon BI, Hwang SY, Kim SW. Cyanidin-3-O- $\beta$ -D-glucopyranoside concentrated materials from mulberry fruit have a potency to protect erectile function by minimizing oxidative stress in a rat model of diabetic erectile dysfunction. *Am J Chin Med*, 2012; 40(2): 349-356.
57. Harauma A, Murayama T, Ikeyama K, Sano H, Arai H, Takano R, Kita T, Hara S, Kamei K, Yokode M. Mulberry leaf powder prevents atherosclerosis in apolipoprotein E-deficient mice. *Biochem Biophys Res Commun*, 2007; 358(3): 751-756.
58. Harper, Douglas. "Pancreas". *Online Etymology Dictionary*. Retrieved 2007-04-04.
59. Hasimoto NM, Genovese MI, Lajola FM. Absorption and metabolism of cyaniding-3-glucoside and cyaniding-3-rutinoside extracted from wild mulberry (*Morus nigra* L.) in rats. *Natr Res*, 2008; 28(3): 198-207.
60. Higa, M.; Zhou, Y. T.; Ravazzola, M.; Baetens, D.; Orel, L.; Unger, R. H. (1999). Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. *Proc. Natl. Acad. Sci. USA*, v.96, p.11513-11518.
61. Hogade MG, Patil KS, Wadkar GH, Mathapati SS, Dhupal PB. Hepatoprotective activity of *Morus alba* (Linn.) leaves extract against carbon tetrachloride induced hepatotoxicity in rats. *Afr J Pharm Pharmacol*, 2010; 4: 731-734.
62. Howard, John M.; Hess, Walter (2012). History of the Pancreas: Mysteries of a Hidden Organ. *Springer Science & Business Media*. p. 24. ISBN 978-1461505556.
63. Hussein MS, El-Tawil OS, Yassin NEH, Abdou KA. The protective effect of *Morus alba* and *Calendula officinalis* plant extracts on carbon tetrachloride-induced hepatotoxicity in isolated rat hepatocytes. *J Amer Sci*, 2010; 6: 762-773.
64. Ihara Y, Toyokuni S, Uchida K, Odaka H, Tanaka T, Ikeda H, et al. Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. *Diabetes*. 1999;48(4):927-32.
65. Imran M, Khan H, Shah M, Khan R, Khan F. Chemical composition and antioxidant activity of certain *Morus* species. *J Zhejiang Univ Sci*, 2011; 11: 973-980.
66. Ionescu-Tirgoviste, Constantin; Gagniuc, Paul A.; Gubceac, Elvira; Mardare, Liliana; Popescu, Irinel; Dima, Simona; Militaru, Manuella (2015-09-29). "A 3D map of the islet routes

- throughout the healthy human pancreas". *Scientific Reports*. 5: 14634. Bibcode:2015NatSR...514634I. doi:10.1038/srep14634. PMC 4586491 . PMID 26417671.
67. Iqbal S, Younas U, Sirajuddin KW, Chan RA, Sarfraz, Uddin MK. Proximate composition and antioxidant potential of leaves from three varieties of mulberry (*Morus* sp.): A comparative study. *Int J Mol Sci*, 2012; 13: 6651-6664.
  68. Isabelle M, Lee BL, Ong CN, Liu X, Huang D. Peroxyl radical scavenging capacity, polyphenolics and lipophilic antioxidant profiles of mulberry fruit cultivated in southern China. *J Agric Food Chem*, 2008; 56(20): 9410-9416.
  69. Jaruchotikamol A, Pannangpetch P. Cytoprotective activity of mulberry leaf extract against oxidative stress-induced cellular injury in rats. *Pak J Pharm Sci*, 2013; 26(1): 163-168.
  70. Jeong JC, Jang SW, Kim TH, Kwon CH, Kim YK. Mulberry fruit (*Morus fructus*) extracts induce human glioma cell death in vitro through ROS-dependent mitochondrial pathway and inhibits glioma tumor growth in vivo. *Nutr Cancer*, 2010; 62(3): 402-412.
  71. Jiang YL, Piao HS, Li G. Study on antioxidant activity of constituents from mulberry leaf. *Zhong Yao Cai*, 2008; 31(4): 519-522.
  72. Jiang, G.; Zhang, B. B. (2003). Glucagon and regulation of glucose metabolism. *Am. J. Physiol. Endocrinol. Metab.*, v.284, p.E671-E678, 2003.
  73. Jin YS, Lee MJ, Han W, Heo SL, Sohn SL, Wang MH. Antioxidant effects and hepatoprotective activity of 2,5-dihydroxy-4,3-di(beta-d-glucopyranosyloxy)-trans-stilbene from *Morus bombycis* Koidzumi roots on CCl<sub>4</sub>-induced liver damage in vivo. *Free Rad Res*, 2006; 40(9): 986-992.
  74. Jin YS, Sa JH, Shim TH, Rhee HI, Wang MH. Hepatoprotective and antioxidant effects of *Morus bombycis* Koidzumi on CCl<sub>4</sub>-induced liver damage. *Biochem Biophys Res Commun*, 2005; 329(3): 991-995.
  75. Kakkar P, Das B, Viswanathan PN. A (1984). modified spectrophotometric assay of superoxide dismutase. *Indian J Biochem Biophys*. 1984;21(2):130-2.
  76. Kalkan YH. Evaluation of colour parameters and antioxidant activities of fruit wines. *Int J Food Sci Nutr*, 2006; 57(1-2): 47-63.
  77. Kang TH, Hur JY, Kim HB, Ryu JH, Kim SY. Neuroprotective effects of the cyaniding-3-O-β-glucopyranoside isolated from mulberry fruit against cerebral ischemia. *Neurosci Lett*, 2006; 391: 168-172.
  78. Kapche GD, Amadou D, Waffo-Teguo P, Donfack JH, Fozing CD, Harakat D, Tchana AN, Merillon JM, Moundipa PF, Ngadjui BT, Abegaz BM. Hepatoprotective and antioxidant arylbenzofurans and flavonoids from the twigs of *Morus mesozygia*. *J Biosci Bioeng*, 2011; 111(6): 675-681.
  79. Kapche GD, Fozing CD, Donfack JH, Fotso GW, Amadou D, Tchana AN, Bezabih M, Moundipa PF, Ngadjui BT, Abegaz BM. Prenylated arylbenzofuran derivatives from *Morus mesozygia* with antioxidant activity. *Biol Phram Bull*, 2009; 32(1): 86-90.
  80. Katsube T, Yamasaki M, Shiwaku K, Ishijima T, Matsumoto I, Abe K, Yamasaki Y. Effect of flavonol glycoside in mulberry (*Morus alba*) leaf on glucose metabolism and oxidative stress in liver in diet-induced obese mice. *J Sci Food Agri*, 2010; 90: 2386-2392.
  81. Kenichi Watanabe. Modulation of endoplasmic reticulum stress and cardiomyocyte apoptosis by mulberry leaf diet in experimental autoimmune myocarditis rats. *J Clinical Biochem Nutri*, 2012; 50(2): 139-144.
  82. Kesari, A. N.; Gupta, R. K.; Singh, S. K.; Diwakar, S.; Watal, G. (2006). Hypoglycemic and antihyperglycemic activity of *Aegle marmelos* seed extract in normal and diabetic rats. *J. Ethnopharmacol.*, v.107, p.374-379.
  83. Khan MA, Rahman AA, Islam S, Khandokhar P, Parvin S, Islam MB, Hossain M, Rashid M, Sadik G, Nasrin S, Mollah MN, Alam AH. A comparative study on the antioxidant activity of

- methanolic extracts from different parts of *Morus alba* L. (*Moraceae*). *BMC Res Notes*, 2013; 6: 24.
84. Kim GN, Jang HD. Flavonol content in the water extracts of the mulberry (*Morus alba* L.) leaf and their antioxidant capacities. *J Food Sci*, 2011; 76(6): C869-C873.
  85. Kim GN, Kwon YI, Jang HD. Mulberry leaf extract reduces postprandial hyperglycemia with few side effects by inhibiting  $\alpha$ -glucosidase in normal rats. *J Med Food*, 2011; 14: 712-717.
  86. Kim HG, Ju MS, Shim JS, Kim MC, Lee SH, Huh Y, Kim SY, Oh MS. Mulberry fruit protects dopaminergic neurons in toxin-induced Parkinson's disease models. *Brit J Nutr*, 2010; 104: 8-16.
  87. Kim SY, Gao JJ, Lee WC, Ryu KS, Lee KR, Kim YC. Antioxidative flavonoids from the leaves of *Morus alba*. *Arch Pharm Res*, 1999; 22(1): 81-85.
  88. Kimura T, Nakagawa K, Kubota H. Food-grade mulberry powder enriched with 1-deoxynojirimycin suppresses the elevation of postprandial blood glucose in humans. *J Agri Food Chem*, 2007; 55: 5869-5874.
  89. Kofujita H, Yaguchi M, Doi N, Suzuki K. A novel cytotoxic prenylated flavonoid from the root of *Morus alba*. *J Insect Biotechnol Sericol*, 2004; 73: 113-116.
  90. Kurian JC. *Plants That Heal*. Vol. 2. Oriental Longman Publishing House. 2007; 92-93.
  91. Kwak EJ, Lee JY, Choi IS. Physicochemical properties and antioxidant activities of Korean traditional alcoholic beverage, Yakju, enriched with mulberry. *Semin Cutan Med Surg*, 2012; 31(2): 133-139.
  92. Lakey, JR; Burrige, PW; Shapiro, AM (September 2003). "Technical aspects of islet preparation and transplantation". *Transplant international : official journal of the European Society for Organ Transplantation*. 16 (9): 613-32.
  93. Lal VK, Gupta PP, Awanish P. Hypoglycemic effect of *kyllinga triceps* in STZ induced diabetic rats. *J Diabetes Metab*. 2012;5.6:1000203.
  94. Lee CY, Cheng HM, Sim SM. Mulberry leaves protect rat tissues from immobilization stress-induced inflammation. *Biofactors*, 2007a; 31(1): 25-33.
  95. Lee CY, Sim SM, Cheng HM. Phenylacetic acids were detected in the plasma and urine of rats administered with low-dose mulberry leaf extract. *Nutr Res*, 2008; 28: 555-563.
  96. Lee CY, Sim SM, Cheng HM. Systemic absorption of antioxidants from mulberry (*Morus alba* L) leaf extracts using an *in situ* rat intestinal preparation. *Nutr Res*, 2007b; 27: 492-497.
  97. Li LN. Biologically active components from traditional Chinese medicines. *Pure Appl Chem*, 1998; 70: 547-554.
  98. Lin JY, Tang CY. Determination of total phenolic and flavonoid contents in selected fruits and vegetables as well as their stimulatory effects on mouse splenocyte proliferation. *Food Chem*, 2007; 101(1): 140-147.
  99. Liu LK, Lee HJ, Shih YW, Chyau CC, Wang CJ. Mulberry anthocyanin extracts inhibit LDL oxidation and macrophage-derived foam cell formation induced by oxidative LDL. *J Food Sci*, 2008; 73(6): H113-H121.
  100. Longo, D; Fauci, A; Kasper, D; Hauser, S; Jameson, J; Loscalzo, J (2012). *Harrison's Principles of Internal Medicine (18th ed.)*. New York: McGraw-Hill. pp. 2995-3000. ISBN 978-0071748896.
  101. Markman, B. E. O.; Bachi, E. M.; Kato, E. T. M. (2004). Anti-ulcerogenic effects of *Campomanesia xanthocarpa*. *J Ethnopharmacol.*, v.94, p.55-57.
  102. Mehdy MC. Active oxygen species in plant defense against pathogens. *Plant Physiol*, 1994; 105: 467-472.
  103. Mehla RK, Patel RK, Tripathi VN. A model for sericulture and milk production. *Agricultural systems*, 1987; 25: 125-133.



104. Miyahara C, Miyazawa M, Satoh S, Sakai A, Mizusaki S. Inhibitory effects of mulberry leaf extract on postprandial hyperglycemia in normal rats. *J Nutr Sci Vitaminol*, 2004; 50: 161-164.
105. Mudra M, Ercan-Fang N, Zhong L. Influence of mulberry leaf extract on the blood glucose and breath hydrogen response to ingestion of 75g sucrose by type-2 diabetic and control subjects. *Diabetes Care*, 2007; 30: 1272-1274.
106. Naderi GA, Asgary S, Sarraf-Zadegan N, Oroojy H, Afshin-Nia F. Antioxidant activity of three extracts of *Morus nigra*. *Phytother Res*, 2004; 18(5): 365-369.
107. Nakagawa K, Ogawa K, Higuchi O, Kimura T, Miyazawa T, Hori M. Determination of iminosugars in mulberry leaves and silkworms using hydrophilic interaction chromatography – tandem mass spectrometry. *Analytical Biochem*, 2010; 404: 217-222.
108. Nakamura M, Nakamura S, Oku T. Suppressive response of confections containing the extractive from leaves of *Morus alba* on postprandial blood glucose and insulin in healthy human subjects. *Nutr Metab, (Lond)*. 2009; 6: 29.
109. Nam S, Jang HW, Shibamoto T. Antioxidant activities of extracts from teas prepared from medicinal plants *Morus alba* L., *Camellia sinensis* L. and *Cudrania tricuspidata* and their volatile components. *J Agric Food Chem*, 2012; 60(36): 9097-9105.
110. Naowaboot J, Pannangpetch P, Kukongviriyapan V, Kongyingyoes B, Kukongviriyapan U. Antihyperglycemic, antioxidant and antiglycation activities of mulberry leaf extract in streptozotocin-induced chronic diabetic rats. *Plant Foods Hum Nutr*, 2009; 64: 116-121.
111. Niehaus WG Jr, Samuelsson B. (1968). Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. *Eur J Biochem*. 1968;6(1):126-30.
112. Niidome T, Takahashi K, Goto Y, Goh SM, Tanaka N, Kamei K. Mulberry leaf extract prevents amyloid beta-peptide fibril formation and neurotoxicity. *Neuroreport*, 2007; 18: 813-816.
113. Nitra N, Kornkanok I, Wiroje K, Sathaporn W, Bhinai H. Quantitative determination of 1-deoxynojirimycin in mulberry leaves using liquid chromatography-tandem mass spectrometry. *J Pharmaceut Biomed Analysis*, 2007; 44(4): 853-858.
114. Nomura T, Fukai T, Kuwanon G. A new flavone derivative from the root barks of the cultivated mulberry tree (*Morus alba* L.). *Chem Pharm Bull*, 1980; 28: 2548-2552.
115. Nuraliev, I. N.; Avezov, G. A. (1992). The efficacy of quercetin in alloxan diabetes. *Eks. Klin. Farmakol.*, v.55, p.42-44.
116. Oh H, Ko EK, Jun JY, Oh MH, Park SU, Kang KH. Hepatoprotective and free radical scavenging activities of prenylflavonoids, coumarin and stilbene from *Morus alba*. *Planta Med*, 2002; 68(10): 932-934.
117. Oliveira, H. C.; Santos, M. P.; Grigulo, R.; Lima, L. L.; Martins, D. T. O.; Lima, J. C. S.; Stoppiglia, L. F.; Lopes, C. F.; Kawashita A, N. H. (2008). Antidiabetic activity of *Vatairea macrocarpa* extract in rats. *J. Ethnopharmacol.*, v.115, p.515-519.
118. Ozgen M, Serce S, Kaya C. Phytochemical and antioxidant properties of anthocyanin rich *Morus nigra* and *Morus rubra* fruits. *Sci Hortic*, 2009; 119: 275-279.
119. Pan G, Lou CF. Isolation of a 1-aminocyclopropane-1-carboxylate oxidase gene from mulberry (*Morus alba* L.) and analysis of the function of this gene in plant development and stresses response. *J Plant Physiology*, 2008; 165: 1204-1213.
120. Paula Domingues Baveloni; Máisa Pavani dos Santos; Gustavo Mitsuo Aiko; Silvia Regina de Lima Reis; Márcia Queiroz Latorraca; Virginia Claudia da Silva; Evandro Luiz Dall'Oglio; Paulo Teixeira de Sousa Júnior; Carbene Franc Lopes' Amanda Martins Baviera and Nair Honda Kawashita (2010). Mechanism of anti-hyperglycemic action of *Vatairea macrocarpa* (Leguminosae): Investigation in peripheral tissues. *Journal of Ethnopharmacology* 131 (2010) 135–139. [www.elsevier.com/locate/jethpharm](http://www.elsevier.com/locate/jethpharm)

121. Perez-Gregorio RM, Regueiro J, Alonso-González EL, Pastrana-Castro M, Simal-Gándara J. Influence of alcoholic fermentation process on antioxidant activity and phenolic levels from mulberries (*Morus nigra* L.). *LWT – Food Sci Tech*, 2011; 44(8): 1793-1801.
122. Pihlanto A, Akkanen S, Korhonen HJ. ACE-inhibitory and antioxidant properties of potato (*Solanum tuberosum*). *Food Chem*, 2008; 109: 104-112.
123. Pirvulesen MM, Gan AM, Stan D, Simion V, Calin M, Butoi E, Tirgoviste CI, Manduteanu I. Curcumin and a *Morus alba* extract reduce pro-inflammatory effects of resistin in human endothelial cells. *Phytother Res*, 2011; 25(12): 1737-1742.
124. Prasad L, Khan TH, Sehrawat A, Sultana S. Modulatory effect of *Morus indica* against two-stage skin carcinogenesis in Swiss albino mice: possible mechanism by inhibiting aryl hydrocarbon hydroxylase. *J Pharm Pharmacol*, 2004; 56(10): 1291-1298.
125. Pushparaj, P. N.; Low, H. K.; Manikandan, J.; Tan, B. K. H.; Tan, C. H. (2007). Anti-diabetic effects of *Cichorium intybus* in streptozotocin-induced diabetic rats. *J. Ethnopharmacol.*, v.111, p.430-434.
126. Revilla-Monsalve, M. C.; Andrade-Cetto, A.; Palomino-Garibay, M. A.; Wiedenfeld, H.; Islas-Andrade, S. (2007). Hypoglycemic effect of *Cecropia obtusifolia* Bertol aqueous extracts on type 2 diabetic patients. *J. Ethnopharmacol.*, v.111, p.636-640.
127. Ross, JA and Kasum, CM (2002). Dietary flavonoids: bioavailability, metabolic effects, and safety. *Annu Rev Nutr*. 2002;22:19-34.
128. Rossetto M, Vanzani P, Lunelli M, Scarpa M, Mattivi F, Rigo A. Peroxyl radical trapping activity of anthocyanins and generation of free radical intermediates. *Free Radic Res*, 2007; 41: 854-859.
129. Sabira Mushtaq and Shail Bala Sanghi (2016). Phytochemical Analysis of the leaves of *Morus alba* (L.) International Journal of Recent Scientific Research Vol. 7, Issue, 12, pp. 14538-14540, December, 2016 <http://www.recentscientific.com>
130. Sakagami H, Asano K, Satoh K, Takahashi K, Terakubo S, Shoji Y, Nakashima H, Nakamura W. Antistress activity of mulberry juice in mice. *In Vivo*, 2006; 20(4): 499-504.
131. Salgado, L. R. (1998). *Diabetes*. São Paulo: Ed. Contexto, 63 p. Savage, D. B.; Petersen, K. F.; Shulman, G. I. (2007). Disordered lipid metabolism and the pathogenesis of insulin resistance. *Physiol. Rev.*, v.87, p.507-520.
132. Sanchez-Salgado, J. C.; Ortiz-Andrade, R. R.; Auirre-Crespo, F.; Vergara-Galicia, J.; Leon-Rivera, I.; Montes, S.; Villalobos-Molina, R.; Estrá-Soto, S. (2007). Hypoglycemic, vasorelaxant and hepatoprotective effects of *Cochlospermum vitifolium* (Willd.) Sprengel: A potential agent for the treatment of metabolic Syndrome *J. Ethnopharmacol.*, v.109, p.400- 405.
133. Schmeda-Hirschmann, G. (1995). Flavonoids from *Calycorectes*, *Campomanesia*, *Eugenia* and *Hexachlamys* species. *Fitoterapia*, v.66, p.373-374.
134. Schoenfelder, T.; Cirimbelli, T. M.; Citadini-Zanette, V. (2006). Acute effect of *Trema micrantha* (Ulmaceae) on serum glucose levels in normal and diabetic rats *J. Ethnopharmacol.*, v.107, p.456-459, 2006.
135. Sharma R, Sharma A, Shono T, Takasugi M, Shirata A, Fujimora T, Machii H. Mulberry moracins: Scavengers of UV-stress generated free radicals. *Biosci Biotechnol Biochem*, 2001; 65(6): 1402-1405.
136. Shibata Y, Kume N, Arai H, Hayashida K, Inui-Hayashida A, Minami M, Mukai E, Toyohara M, Harauma A, Murayama T, Kita T, Hara S, Kamei K, Yokode M. Mulberry leaf aqueous fractions inhibit TNF-alpha-induced nuclear factor kappaB (NF-kappaB) activation and lectin-like oxidized LDL receptor-1 (LOX-1) expression in vascular endothelial cells. *Atherosclerosis*, 2007; 193(1): 20-27.

137. Shih PH, Chan YC, Liao JW, Wang MF, Yen GC. Antioxidant and cognitive promotion effects of anthocyanin-rich mulberry (*Morus atropurpurea*) on senescence accelerated mice and prevention of Alzheimer's disease. *Plant Foods Hum Nutr*, 2009; 64(2): 116-121.
138. Singhal BK, Khan MA, Dhar A, Baqual FM, Bindroo BB. Approaches to industrial exploitation of mulberry (*Morus* sp.) fruits. *J Fruit Ornam Plant Res*, 2010; 18(1): 83-99.
139. Singhania N, Puri D, Madhu SV, Sharma SB. Assessment of oxidative stress and endothelial dysfunction in Asian Indians with type 2 diabetes mellitus with and without macroangiopathy. *QJM*, 2008; 101(6): 449-455.
140. Sinha AK. (1972). Colorimetric assay of catalase. *Anal Biochem*. 1972;47(2):389-94.
141. Somasundaram A, Arumugam, Rajarajan T, Thandavarayan, Punniyakoti, Veeraveedu, Meilei Ma V, Vijayasree, Giridharan, Wawaimuli Arozal R, Flori, Sari, Vijayakumar Sukumaran, Arunprasath Lakshmanan, Vivian Soetikno, Kenji Suzuki, Makoto Kodama,
142. Song W, Wang HJ, Bucheli P, Zhang PF, Wei DZ, Lu YH. Phytochemical profiles of different mulberry (*Morus*) species from China. *J Nutr Biochem*, 2010; 21(7): 598-605.
143. Sreelatha S, Padma PR. Antioxidant activity and total phenolic content of *Moringa oleifera* leaves in two stages of maturity. *Plant Foods Hum Nutr*, 2009; 64: 303-311.
144. Srivastava R, Kapoor A, Thathola RP, Srivastava. Mulberry (*Morus alba*) leaves as human food: a new dimension of sericulture. *Int J Food Sci Nutr*, 2003; 54: 411-416.
145. Stahl W, Sies H. (1997). Antioxidant defense: vitamins E and C and carotenoids. *Diabetes*. 1997;46 Suppl 2:S14-8.
146. Stumvoll, M.; Goldstein, B. J.; Van Haeften, T. W. (2005). Type 2 diabetes: principles of pathogenesis and therapy. *Seminar.*, v.365, p.1333-1346.
147. Sun F, Shen LM, Ma ZJ. Screening for ligands of human aromatase from mulberry (*Morus alba* L.) leaf by using high-performance liquid chromatography/ tandem mass spectrometry. *Food Chem*, 2011; 126: 1337-1343.
148. Tamara M. Green (2008). The Greek and Latin Roots of English. Rowman & Littlefield. p. 176. ISBN 978-0742547803.
149. Tan YX, Liu C, Chen R. Phenolic constituents from stem bark of *Morus wittiorum* and their anti-inflammation and cytotoxicity. *Zhongguo Zhong Yao Za Zhi*, 2010; 35(20): 2700-2703.
150. Tang, L. Q.; Wei, W.; Chen, L. M.; Liu, S. (2006). Effects of berberine on diabetes induced by alloxan and a high-fat/ high cholesterol diet in rats. *J. Ethnopharmacol.*, v.108, p.109-115.
151. Teckman, J. H.; An, J. K.; Loethen, S.; Perlmutter, D. H. (2002). Fasting in al-antitrypsin deficient liver: constitutive activation of autophagy. *Am. J. Physiol.*, v.263, p.G1156-G1165.
152. Terry O'Brien (2015). A2Z Book of word Origins. Rupa Publications. p. 86. ISBN 978-8129118097.
153. Tewari RK, Kumar P, Sharma PN. Antioxidant responses to enhanced generation of superoxide anion radical and hydrogen peroxide in the copper-stressed mulberry plants. *Fitoterapia*, 2005; 76(7-8): 608-613.
154. Thorup, C.; Ollerstam, A.; Persson, E. G.; Torffvit, O. (2000). Increased tubuloglomerular feedback reactivity is associated with increased NO production in the streptozotocin-diabetic rat. *J. Diabetes Compl.*, v.14, p.46-52.
155. Tian J, Fu F, Geng M, Jiang Y, Yang J, Jiang W, Wang C, Liu K. Neuroprotective effect of 20(S)-ginsenoside Rg3 on cerebral ischemia in rats. *Neurosci Lett*, 2005; 374: 92-97.
156. Tiwari, A. K.; Rao, J. M. (2002). Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospects. *Curr. Sci.*, v.83, p.30-38.
157. Tokuyama Y, Sturis J, DePaoli AM, Takeda J, Stoffel M, Tang J, et al. (1995). Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. *Diabetes*. 1995;44(12):1447-57.

158. Toloso, E. M. C.; Rodrigues, C. J.; Behmer, A. O.; Neto, A. G. F. (2003). Manual de técnicas para histologia normal e patológica. 2.ed. São Paulo: Ed. Manole, p.311.
159. Van Der Laar FA, Lucassen PL, Akkermans RP.  $\alpha$ -Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. *Diabetes Care*, 2005; 28: 154-163.
160. Van Handel, E. (1965). Determination of glycogen in small amounts of tissue. *Anal. Biochem.*, v.11, p.256-265.
161. Venkatesh Kumar R, Seema Chauhan. Mulberry: Life enhancer. *J Medicinal Plants Research*, 2008; 2(10): 271-278.
162. Vessal, M.; Hemmati, M.; Vasei, M. (2003). Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. *Comp. Biochem. Physiol.*, part C, v.135, p.357-364.
163. Vijayan K, Srivastava PP, Awasthi AK. Analysis of phylogenetic relationship among five mulberry (*Morus*) species using molecular markers. *Genome*, 2004; 47: 439-448.
164. Vitthalrao B. Khyade (2014). Effect of leaf extractives of Mulberry, *Morus alba* (L.) on biochemical parameters in Diabetic Rats. International Multidisciplinary e-Journal ISSN 4262 Vol-III, Issue-III, March -2014: 22 – 33. [www.shreeprakashan.com](http://www.shreeprakashan.com)
165. Vitthalrao B. Khyade and Sadhana D. Deshpande (2015). Chemopreventive Efficacy of Ethanolic Extractives of Leaves of Mulberry, *Morus alba* (L.) On 7, 12-Dimethylbenz Anthracene (DMBA) Induced Buccal Pouch Carcinoma in Syrian Hamster, *Mesocricetus auratus* (L). International Journal of Recent Scientific Research, Vol. 6, Issue, 3, pp.3156-3161, March, 2015. [www.recentscientific.com](http://www.recentscientific.com)
166. Vitthalrao Bhimasha Khyade (2018). Leaf Decoction of Mulberry, *Morus alba* (L.) for management of Streptozotocin Induced Diabetes in Brown Rat, *Rattus norvegicus* (L.). International Journal of Scientific Research in Chemistry (IJSRCH) ISSN: 2456-8457. 2018 IJSRCH. Volume 3, Issue 4: 89 – 114. <http://ijsrch.com/paper/IJSRCH183412.pdf>
167. Volpato GT, Calderon IM, Sinzato S, Campos KE, Rudge MV, Damasceno DC. Effect of *Morus nigra* aqueous extract treatment on the maternal-fetal outcome, oxidative stress
168. Wang L, Yang Y, Liu C, Chen RY. Three new compounds from *Morus nigra* L. *J Asian Nat Prod Res*, 2010; 12: 431-437.
169. Wang W, Zu Y, Fu Y, Efferth T. In vitro antioxidant and antimicrobial activity of extracts from *Morus alba* L. leaves, stems and fruits. *J Food Sci*, 2011; 76(6): 869-873.
170. World Health Organization (2008). Diabetes Programme. Available at: <http://www.who.int/diabetes>.
171. Yang MY, Huang CN, Chan KC, Yang YS, Peng CH, Wang CJ. Mulberry leaf polyphenols possess anti-atherogenesis effect via inhibiting LDL oxidation and foam cell formation. *J Agric Food Chem*, 2011; 59(5): 1985-1995.
172. Yang X, Yang L, Zheng H. Hypolipidemic and antioxidant effects of mulberry (*Morus alba* L.) fruit in hyperlipidemia rats. *Food Chem Toxicol*, 2010; 48(8-9): 2374-2379.
173. Yogananda Murthy VN, Ramesh HL, Lokesh G, Munirajappa, Dayakar Yadav BR. Leaf quality evaluation of ten mulberry (*Morus*) germplasm varieties through phytochemical analysis. *Int J Pharm Sci Rev Res*, 2013; 21(1): 182-189.
174. Yu Z, Fong WP, Cheng CH. Morin (3,5,7,2'',4''-pentahydroxyflavone) exhibits potent inhibitory actions on urate transport by the human urate anion transporter (hURAT1) expressed in human embryonic kidney cells. *Drug Metab Dispos*, 2007; 35: 981-986.
175. Zafar MS, Muhammad F, Javed I, Akhtar M, Khaliq T, Aslam B, Waheed A, Yasmin R, Zafar H. White mulberry (*Morus alba*): A brief phytochemical and pharmacological evaluations account. *Int J Agric Biol*, 2013; 15: 612-620.

176. Zhang M, Chen M, Zhang HQ, Sun S, Xia B, Wu FH. In vivo hypoglycemic effects of phenolics from the root bark of *Morus alba*. *Fitoterapia*, 2009; 80(8): 475-477.
177. Zhang W, Han F, Duan C. HPLC-DAD-ESI-MS/MS analysis and antioxidant activities of non-anthocyanin phenolics in mulberry (*Morus alba* L.). *J Food Sci*, 2008; 73(51): 512-518.
178. Zheng ZP, Tan HY, Wang M. Tyrosinase inhibition constituents from the root of *Morus australis*. *Fitoterapia*, 2012; 83(6): 1008-1013.
179. Zhong L, Furne JK, Levitt MD. An extract of black, green and mulberry teas causes malabsorption of carbohydrate but not of triacylglycerol in healthy volunteers. *Am J Clin Nutr*, 2006; 84: 551-555.
180. Zou Shengqin, Chen Wu. A review on chemical constituents, pharmacological activity and application of mulberry leaves. *J Chem Indus Forest Products*, 2003; 1: 22-25.
181. Triplitt CL, Reasner CA. Diabetes mellitus. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. *Pharmacotherapy - A Pathophysiologic Approach*. 8th Edition, Volume 83. China: McGraw-Hill Companies; 2011:1255-302.
182. Al-Enazi MM. Combined therapy of rutin and silymarin has more protective effects on STZ-induced oxidative stress in rats. *J Appl Pharm Sci*. 2014;4(01):021-8.
183. Balkis Budin S, Othman F, Louis SR, Abu Bakar M, Radzi M, Osman K, et al. Effect of alpha lipoic acid on oxidative stress and vascular wall of diabetic rats. *Rom J Morphol Embryol*. 2009;50(1):23-30.
184. Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. *Diabetes Metab Syndr Obes*. 2011;4:307-13.
185. Arivazhagan P, Thilakavathy T, Panneerselvam C. Antioxidant lipoate and tissue antioxidants in aged rats. *J Nutr Biochem*. 2000;11(3):122-7.
186. Powers AC. Diabetes mellitus. In: Kasper DL, Fauci AS, Longo D, Braunwald E, Hauser SC, Jameson JL, editors. *Harrison's Principles of Internal Medicine*. 16th Edition, Volume 323. New York: McGraw-Hill Book Co.; 2005: 2152-62.
187. Varzi HN, Esmailzadeh S, Morovvati H, Avizeh R, Shahriari A, Givi ME. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. *J Vet Pharmacol Ther*. 2007;30(5):477-81.